Horizon Discovery (Horizon) today announced it has signed a material transfer agreement with Sunesis Pharmaceuticals, Inc., (Sunesis) relating to its X-MAN technology.
Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to rationalize key steps of the ‘targeted’ drug development process, and thus accelerate and economize the burgeoning field of ‘personalised’ medicine.
The agreement covers the screening of Sunesis’ lead compound, voreloxin, a first-in-class anticancer quinolone derivative (AQD), on certain human isogenic cell-lines comprising target genotypes of interest to Sunesis. The approach may enable Sunesis to gather information relating to the selectivity and mode-of-action of voreloxin using model in-vitro systems.
Dr. Darrin M. Disley, Chairman of Horizon said “working with Sunesis is an exciting development for Horizon. In this agreement, we hope to further prove the potential of our human X-MAN models in a drug screening / profiling environment”. The agreement begins in February 2010 for an initial period of 12 months.